|Day Low/High||0.23 / 0.26|
|52 Wk Low/High||0.14 / 0.98|
Imagine a derailed freight train carrying dumpsters on fire. That's an accurate description of the Northwest Bio 10-K filed Monday night.
Northwest's inability to resolve the problems that froze the DCVax-L clinical trial -- and management's refusal to offer a public explanation for why it happened -- triggered the company's collapse.
Northwest Biotherapeutics, a regular visitor to the capital markets, has negotiated a note payment schedule with Whitebox Advisors.
Process Now Moving Forward Toward Data Lock
TheStreet's biotech columnist offers his own report card on biotech stocks.
Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
The cancer immunotherapy company's cash position has plunged to the point where it may no longer be capable of paying its operating expenses.
A defrocked analyst brushes off the serious problems weighing on Northwest Bio. Instead, he jacks the tired 'blame the shorts' excuse to another level.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
These under-$10 stocks are making big moves higher. Here's how to trade them from here.
TheStreet's Senior Columnist Adam Feuerstein answers reader questions about biotech stocks.
Frank comments and a warning from a doctor supervising pivotal brain cancer vaccine study for Northwest Bio are likely cause of sharp slide in stock price.
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the March 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new March 18th contracts and identified the following put contract of particular interest.
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
Investors in Northwest Biotherapeutics Inc saw new options become available this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new December 18th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Northwest Biotherapeutics Inc saw new options begin trading this week, for the November 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NWBO options chain for the new November 20th contracts and identified the following call contract of particular interest.
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
Investors in Northwest Biotherapeutics Inc saw new options begin trading today, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Northwest Biotherapeutics, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of...